Agios Q3 2022: PYRUKYND revenue $3.5M, 56 patients on therapy; CHMP positive opinion received

AGIOS PHARMACEUTICALS, INC.

2022-Q3 EPS reported -$4.90 revenue$9,930,000

PYRUKYND net revenue $3.5M in Q3 2022; 56 patients on therapy (+51% Q/Q), 84 patients enrolled (+64%).
Received positive CHMP opinion for PYRUKYND in adult PK deficiency; filed with UK MHRA.
Cash $1.0B as of Sept 30; subsequently received $131.8M from sale of TIBSOVO royalty rights.
Net loss from continuing ops $81.7M vs $84.3M in Q3 2021; R&D $65.0M, SG&A $29.1M.
Appointed Cecilia Jones as CFO; Rahul Ballal and Cynthia Smith to board of directors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AGIOS PHARMACEUTICALS, INC. reported third quarter ended September 30, 2022 results: revenue $3.5 million, net income Net loss from continuing operations was $81.7 million.

Period: third quarter ended September 30, 2022
Revenue: $3.5 million
Net income: Net loss from continuing operations was $81.7 million
Result: reported results

Exact text from the filing

Quarter 2022 Financial Results – U.S. PYRUKYND ® (mitapivat) Launch Provides Capability Building Platform to Support Expected Future Product Growth and Expansion; Net Revenue of $3.5 Million in Q3 – – Received Positive CHMP Opinion for PYRUKYND ® in Adults with Pyruvate Kinase (PK) Deficiency – – On Track to Meet Year-end Enrollment Targets in PYRUKYND ® Thalassemia

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001439222-22-000098

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.